Fly News Breaks for January 23, 2020
Jan 23, 2020 | 05:14 EDT
Piper Sandler analyst Joseph Catanzaro raised his price target for Ocular Therapeutix to $5.50 from $5.00 and keeps an Overweight rating on the shares after conducting a survey of 25 high-volume surgeons to gauge Dextenza use in Q4 and overall physician sentiment. The survey work points to favorable trends in Dextenza utilization and feedback that continues to skew positively, Catanzaro tells investors in a research note. As a result, the analyst believes that this Q4 estimate of $1.0M is "readily achievable."
News For OCUL From the Last 2 Days
There are no results for your query OCUL